Menu
close
Menu
close
Menu
close
Menu
close
Menu
close
Menu
close

Open Innovation

We believe better access to scientific data can improve patient care and yield scientific breakthroughs to advance precision medicine.
Home breadcrumb-arrow Open Innovation

Revolutionary alliances

We work with like-minded academic partners that focus on patient-centric innovation. Each member of our community gives and receives knowledge to help shape the future of medicine.

Academic Centers

Life Science Companies

Start-Ups

BioPharma Companies

Technology Companies

AVP Projec

We partner with leading academic centers to expand the reach of cutting-edge technologies and accelerate the development of transformative solutions.

For instance, we partner with Memorial Sloan Kettering Cancer Center (MSK), one of the top cancer centers in the world, to combine the cutting-edge capabilities of our SOPHiA DDM™ Platform with the clinical expertise of MSK in cancer genomics to decentralize MSK’s world-class proprietary cancer sequencing tests.

An additional example is the acquisition of the cutting-edge Nénuphar radiomics technology from INRIA and Bordeaux University, which we integrated into our platform to initiate our multimodal journey. This addition enables researchers to unlock novel insights from images, allowing for complex decisions to be made earlier in their studies.
Learn More
“We’re pleased to be collaborating with SOPHiA GENETICS to bring our advanced precision oncology tools to a more diverse, global population of people with cancer through the decentralized SOPHiA DDM™ Platform. We believe accelerating access to precision medicine, both in research and in patient care settings, can improve cancer care and yield a wealth of scientific data to advance our shared mission of reducing the burden of cancer worldwide.”
Kojo S. J. Elenitoba-Johnson, MD
Chair of the Department of Pathology and Lab Medicine
Memorial Sloan Kettering Cancer Center

AVP Projec

We partner with leaders in the life sciences space to optimize the daily workflow of healthcare professionals, enabling them to save time and reduce costs while pursuing precision care.

For example, our collaboration with Danaher’s Integrated DNA Technologies (IDT), a best-in-class genomics reagents provider, allows us to offer a complete NGS workflow that delivers robust results, empowering healthcare professionals to perform high quality genomic analysis in-house.

We also work with Hamilton, a leader for liquid handling automation, to provide a efficient end-to-end workflow. This all-in-one solution increases throughput and ensures the highest possible data integrity and quality, supporting optimal outcomes.
Learn More

“Through this collaboration, we aim to enable the widespread application of precision medicine in oncology across Africa, and thus contributing to the improvement of patient outcomes across the African continent.

“Our partnership with SOPHiA GENETICS strengthens our common goal of providing best-in-class solutions that ultimately help improve people’s lives. By providing a foundation of the most consistent and highest quality reagents, IDT is supporting SOPHiA in the all-important steps of translating data into actionable insights for the entire precision medicine journey, from discovery to diagnostics.”
Mirna Jarosz
Former General Manager of NGS
IDT
Microsoft

AVP Projec

We share a vision with many start-ups to ignite change in the precision medicine field and partner with like-minded organizations to enhance the development of innovative solutions.

For instance, we acquired Interactive Biosoftware, the creators of Alamut, the most widely used decision support software for the visualization and interpretation of genomic data. This powerful and highly complementary technology to the SOPHiA DDM™ Platform further strengthens our commitment to accelerating the global adoption of data-driven medicine.

Another example is our collaboration with Gimli to optimize and automate data collection from Electronic Health Records (EHRs), reducing the manual effort required for clinical trial data management. In the context of the 
DEEP-Lung-IV study, this collaboration improves efficiency, enhances data quality, and supports time and resource savings for the healthcare organizations participating in this clinical trial.
“Interactive Biosoftware has been highly successful in providing powerful technology for experts with complex genomic interpretation needs. It is great to join SOPHiA GENETICS unique approach and position to accelerate data-driven medicine’s adoption.”
André Blavier
Former CEO & Founder
Interactive Biosoftware

AVP Projec

Our leading expertise in transforming massive volumes of complex, real-world data into actionable insights, makes us an invaluable partner for BioPharma companies, supporting them throughout the drug development continuum to accelerate the delivery of precision therapy to market.

One key example to highlight is our collaboration with AstraZeneca, which began in 2021 and spans a multitude of projects centered on harnessing diverse data to facilitate innovative drug development and research efforts. Together we have piloted proof-of-concept multimodal studies for specific cancers, deployed world-class technologies to healthcare institutions and laboratories worldwide, and enabled trial match opportunities, driving advancements in precision oncology.

We also developed SOPHiA UNITY, a global network of best-in-class healthcare institutions contributing high-quality multimodal data. This network generates evidence that will further accelerate cancer research, advance drug development, and support data-driven decision making in cancer care. The volume and scale of this data, analyzed by the SOPHiA DDM™ Platform’s best-in-class artificial intelligence and machine learning, supports biopharma institutions and academic researchers who are solving for the toughest challenges in cancer care today.
Learn More
“We are deeply committed to bringing liquid biopsy expertise to labs and institutions throughout the globe at an expedited pace, and are confident this rollout will further support access to testing and aid in providing data-driven treatment options to patients around the world.”
Kristina Rodnikova
Head of Global Oncology Diagnostics
AstraZeneca

AVP Projec

We partner with leading technology companies to integrate cutting-edge innovations into our platform to empower insightful analysis of increasing volumes of data, while continuously enhancing our security measures to uphold our long-standing commitment to data protection.

For instance, Microsoft Azure hosts our SOPHiA DDM™ Platform, providing secure, scalable cloud infrastructure for a safe and reliable data processing. Azure’s unique, multilayered, built-in security controls ensure confident data processing and insights generation, further reinforcing our ISO recognition for our longstanding commitment to data protection and cloud security.

A perfect example of our commitment to advance computing is our collaboration with NVIDIA. By leveraging powerful NVIDIA Parabricks GPUs, we efficiently process computationally heavy workloads, particularly for our Whole Genome Solution application, enabling researchers to make same-day data-driven decisions. Compatible with leading sequencers, Parabricks supports diverse bioinformatics workflows and integrates AI for improved accuracy and customization.
Learn More

“Through this collaboration, we aim to enable the widespread application of precision medicine in oncology across Africa, and thus contributing to the improvement of patient outcomes across the African continent.

“Microsoft aims to propel healthcare and life sciences into an exciting new era of personalized medicine, helping unlock transformative possibilities for patients worldwide. Our longstanding work with SOPHiA GENETICS will have the potential to democratize data-driven medicine and accelerate vital health research globally.”
Peter Durlach
Corporate Vice President, Health & Life Sciences
Microsoft
“We’re pleased to be collaborating with SOPHiA GENETICS to bring our advanced precision oncology tools to a more diverse, global population of people with cancer through the decentralized SOPHiA DDM™ Platform. We believe accelerating access to precision medicine, both in research and in patient care settings, can improve cancer care and yield a wealth of scientific data to advance our shared mission of reducing the burden of cancer worldwide.”
Kojo S. J. Elenitoba-Johnson,MD
Chair of the Department of Pathology and Lab Medicine
Memorial Sloan Kettering Cancer Center

Lorem ipsum dolor sit amet

Sum dolor sit amet, consectetur adipiscing elit. Quisque vitae erat id arcu iaculis placerat. scelerisque nibh ligula, nec placerat urna tempus nec. Pellentesque eu dui mi.
Nunc urna arcu, viverra vitae augue sit amet, convallis vestibulum diam. Aenean id risus ut quam venen.

Lorem ipsum dolor sit amet

Sum dolor sit amet, consectetur adipiscing elit. Quisque vitae erat id arcu iaculis placerat. scelerisque nibh ligula, nec placerat urna tempus nec. Pellentesque eu dui mi.
Nunc urna arcu, viverra vitae augue sit amet, convallis vestibulum diam. Aenean id risus ut quam venen.
CTA Placeholder

“Through this collaboration, we aim to enable the widespread application of precision medicine in oncology across Africa, and thus contributing to the improvement of patient outcomes across the African continent.

We believe our scientific expertise, combined with AI-enabled technologies and data-driven solutions enabled by SOPHiA GENETICS, presents a unique opportunity to fundamentally transform the journey of cancer patients through non-invasive cancer analysis, predictive genomic testing, and effective precision medicine”.

Abasi Ene-Obong, PhD.
Founder, Syndicate Bio

Let’s advance data-driven medicine, together

Request a Demo of the SOPHiA DDM™ Platform
Contact Us

SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.

SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us at [email protected] to obtain the appropriate product information for your country of residence.

All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.

SOPHiA DDM™ Overview
SOPHiA DDM™ for Genomics
SOPHiA DDM™ for Radiomics
SOPHiA DDM™ for Multimodal
Professional Services
SOPHiA DDM™ Overview
Unlocking Insights, Transforming Healthcare
Learn About SOPHiA DDM™ 
SOPHiA DDM™ for Genomics

Oncology 

Rare and Inherited Disorders

Add-On Modules

SOPHiA DDM™ for Radiomics
Unlock entirely novel insights from your radiology images
Learn About SOPHiA DDM™ for Radiomics 
SOPHiA DDM™ for Multimodal
Explore new frontiers in biology and disease through novel insights
Learn About SOPHiA DDM™ for Multimodal
Professional Services
Accelerate breakthroughs with our tailored enablement services
Learn About our Professional Services